HC Wainwright set a $5.00 price objective on Pieris Pharmaceuticals (NASDAQ:PIRS) in a research report sent to investors on Wednesday morning, The Fly reports. The brokerage currently has a buy rating on the biotechnology company’s stock.
Separately, BidaskClub raised shares of Pieris Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, July 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $10.00.
Shares of PIRS traded down $0.30 on Wednesday, hitting $3.56. 610,604 shares of the stock traded hands, compared to its average volume of 455,000. The company has a market capitalization of $204.79 million, a P/E ratio of -8.90 and a beta of 1.94. Pieris Pharmaceuticals has a one year low of $3.24 and a one year high of $9.75.
Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.04. The company had revenue of $8.35 million during the quarter, compared to the consensus estimate of $6.16 million. Pieris Pharmaceuticals had a negative net margin of 17.90% and a negative return on equity of 19.35%. As a group, equities analysts predict that Pieris Pharmaceuticals will post -0.49 earnings per share for the current fiscal year.
In other news, Director Christopher P. Kiritsy purchased 5,000 shares of Pieris Pharmaceuticals stock in a transaction that occurred on Friday, September 14th. The stock was bought at an average price of $5.11 per share, with a total value of $25,550.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $51,100. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.07% of the stock is owned by company insiders.
A number of hedge funds have recently modified their holdings of PIRS. A.R.T. Advisors LLC purchased a new stake in Pieris Pharmaceuticals in the first quarter worth approximately $103,000. Public Employees Retirement System of Ohio purchased a new stake in Pieris Pharmaceuticals in the second quarter worth approximately $110,000. Marshall Wace LLP purchased a new stake in Pieris Pharmaceuticals in the second quarter worth approximately $118,000. Fox Run Management L.L.C. purchased a new stake in Pieris Pharmaceuticals in the second quarter worth approximately $124,000. Finally, Bowling Portfolio Management LLC purchased a new stake in Pieris Pharmaceuticals in the second quarter worth approximately $156,000. Institutional investors own 65.26% of the company’s stock.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Read More: NASDAQ Stock Market Explained
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.